Read this manager's filing book
Disclosed positions
Stonepine Capital Management, LLC: source evidence dated 2026-08-18T03:59:59.999Z.
- Issuer
- VERASTEM INC
- Ticker
- VSTM
- Class
- COM NEW
- Reported value
- $12,795,575
- Reported amount
- 3,349,627
- Unit
- SH
- Option
- None
The displayed owner or issuer and source fields identify the receipt to verify; keep reporting and availability dates separate.
What was reported for this quarter?
13F positions are dated quarter-end holdings, with later publication and possible amendments. Read report period and availability before calling them current.
SEC 13F-HR/A: 0001440771-26-000016Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filings
Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filingsKeep reporting dates and units beside the answer, and inspect its original citations.
Disclosed positions
See the complete disclosed positions
Scroll sideways to compare all columns. Select a heading to sort.
| VERASTEM INC | VSTM | COM NEW | $12,795,575 | 3,349,627 | SH | None |
| EVOLUS INC | EOLS | COM | $11,035,724 | 1,590,162 | SH | None |
| TENAX THERAPEUTICS INC | TENX | COM NEW | $9,603,000 | 660,000 | SH | None |
| NEKTAR THERAPEUTICS | NKTR | COM NEW | $8,422,856 | 120,654 | SH | None |
| ADMA BIOLOGICS INC | ADMA | COM | $7,950,000 | 650,000 | SH | Call |
| ADMA BIOLOGICS INC | ADMA | COM | $6,193,800 | 740,000 | SH | None |
| CAMP4 THERAPEUTICS CORP | CAMP | COM 13469V AB 4 CAMTEK LTD NOTE 12/0 | $6,072,648 | 1,389,622 | SH | None |
| INSMED INC | INSM | COM PAR $.01 | $5,600,000 | 40,000 | SH | Call |
| ELOXX PHARMACEUTICALS INC | ELOX | COM NEW | $5,512,581 | 397,160 | SH | None |
| ULTRAGENYX PHARMACEUTICAL IN | RARE | COM | $5,500,000 | 200,000 | SH | Call |
| KAZIA THERAPEUTICS LTD | KZIA | SPONSORED ADS | $4,860,120 | 345,179 | SH | None |
| MEDTRONIC PLC | MDT | SHS | $4,375,000 | 50,000 | SH | Call |
| INDIVIOR PHARMACEUTICALS INC | INDV | COM | $4,103,000 | 100,000 | SH | None |
| CORBUS PHARMACEUTICALS HLDGS | CRBP | COM NEW | $3,986,500 | 425,000 | SH | None |
| ABBOTT LABORATORIES | ABT | COM | $3,800,000 | 40,000 | SH | Call |
| SATELLOS BIOSCIENCE INC | MSLE | COM | $3,723,291 | 491,624 | SH | None |
| ZEVRA THERAPEUTICS INC | ZVRA | COM NEW | $3,709,772 | 258,701 | SH | None |
| ABEONA THERAPEUTICS INC | ABEO | COM NEW | $3,444,015 | 557,284 | SH | None |
| BOSTON SCIENTIFIC CORP | BSX | COM | $3,250,000 | 50,000 | SH | Call |
| EDESA BIOTECH INC | EDSA | COM NEW | $3,190,807 | 456,439 | SH | None |
| EVOLUS INC | EOLS | COM | $3,150,000 | 420,000 | SH | Call |
| BIOMARIN PHARMACEUTICAL INC | BMRN | COM | $3,125,000 | 50,000 | SH | Call |
| CABALETTA BIO INC | CABA | COM | $2,852,181 | 917,100 | SH | None |
| AN2 THERAPEUTICS INC | ANTX | COM | $2,670,190 | 551,692 | SH | None |
| XILIO THERAPEUTICS INC | XLO | COM | $2,165,023 | 225,994 | SH | None |
| ADICET BIO INC | ACET | COM NEW | $2,121,276 | 245,518 | SH | None |
| XERIS BIOPHARMA HOLDINGS INC | XERS | COM | $2,100,000 | 280,000 | SH | Call |
| TELA BIO INC | TELA | COM | $1,996,820 | 2,662,427 | SH | None |
| AYTU BIOPHARMA INC | AYTU | COM | $1,962,780 | 912,921 | SH | None |
| CURIS INC | CRIS | COM | $1,729,292 | 3,312,185 | SH | None |
| SPRUCE BIOSCIENCES INC | SPRB | COM NEW | $1,554,930 | 28,795 | SH | None |
| HERON THERAPEUTICS INC | HRTX | COM | $1,500,000 | 1,000,000 | SH | Call |
| SI BONE INC | SIBN | COM | $1,500,000 | 100,000 | SH | Call |
| OKYO PHARMA LTD | Unresolved | SHS NEW | $1,294,494 | 862,996 | SH | None |
| NEUMORA THERAPEUTICS INC. | NMRA | COM | $1,250,000 | 500,000 | SH | Call |
| PASITHEA THERAPEUTICS CORP | KTTA | COM NEW | $1,134,637 | 2,201,468 | SH | None |
| SOL-GEL TECHNOLOGIES LTD | Unresolved | SHS NEW | $1,072,732 | 14,469 | SH | None |
| PULMONX CORP | LUNG | COM | $1,060,067 | 815,436 | SH | None |
| X4 PHARMACEUTICALS INC | XFOR | COM NEW | $1,050,699 | 224,989 | SH | None |
| ARDELYX INC | ARDX | COM | $1,050,000 | 150,000 | SH | Call |
| DELCATH SYS INC | DCTH | COM NEW | $1,000,000 | 100,000 | SH | Call |
| IN8BIO INC | INAB | COM NEW | $980,355 | 695,287 | SH | None |
| MOONLAKE IMMUNOTHERAPEUTICS | MLTX | CLASS A ORD | $973,500 | 50,000 | SH | None |
| QUOIN PHARMACEUTICALS LTD | QNRX | SPONSORED ADS | $965,512 | 199,486 | SH | None |
| MAXCYTE INC | MXCT | COM | $924,475 | 751,606 | SH | None |
| PHATHOM PHARMACEUTICALS INC | PHAT | COM | $922,358 | 85,010 | SH | None |
| AZITRA INC | AZTR | COM NEW | $886,903 | 5,285,476 | SH | None |
| CONNECT BIOPHARMA HLDGS LTD | Unresolved | SHS | $866,925 | 364,254 | SH | None |
| CYBIN INC | HELP | COM NEW | $854,541 | 129,280 | SH | None |
| ULTRAGENYX PHARMACEUTICAL IN | RARE | COM | $834,750 | 25,000 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 5 positions lack a resolved ticker and 15 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.